Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation

Snakebite remains a neglected medical problem of the developing world with up to 125,000 deaths each year despite more than a century of calls to improve snakebite prevention and care.An estimated 75% of fatalities from snakebite occur outside the hospital setting.Because phospholipase A2 (PLA2) activity is an important component of venom toxicity,

read more